It is predicted that the global stem cell treatment market will exceed 100 billion US dollars by 2021, and the global stem cell treatment market will reach 200 billion US dollars in 2024.

Recently, “Huawei Biological” announced the completion of a new round of tens of millions of dollars in financing. This round of financing will be funded by Guoke Jiahe and the leading investment, common investment, Shuimu Tsinghua Alumni Fund, Huaxue Foundation Fund team, and Tsinghua University. The funds will be used for the construction of GMP plant, and then the product line will be scaled up. The registration of the product lays the foundation.

Beijing Huasheng Biotechnology Co., Ltd. (hereinafter referred to as: Huasheng Bio) was established in August 2018, mainly Engaged in the research and development of 3D micro-tissue engineering technology, stem cell culture proliferation amplification, 3D stem cell micro-tissue regeneration treatment and 3D cell high-throughput drug screening product development.

Foresight Industry Research Institute’s “China Stem Cell Therapy Technology Industry Market Prospects and Investment Potential Analysis Report According to statistics, the global stem cell treatment market grew by more than US$50 billion in 2017, reaching US$51.26 billion. It is predicted that the global stem cell treatment market will exceed 100 billion US dollars in 2021, and the global stem cell treatment market will reach 200 billion US dollars in 2024.

Huawei Biological CEO Liu Wei said that the company team was born in the team of Professor Du Yanan from Tsinghua University School of Medicine. Professor Du Yanan has been engaged in basic research since returning to Harvard Medical School in August 2010. After 8 years, the team has realized the leap from technology development to achievement transformation. “We are a typical case of a full-time entrepreneurship of a university research team.”

Different from the traditional two-dimensional artificial culture, Huasheng Bio has developed a set of customized stem cell three-dimensional culture system, including stem cell three-dimensional culture and amplification microcarrier products and supporting kits, stem cell three-dimensional Automated large-scale culture equipment, establishment of three-dimensional stem cell expansion culture process standards (SOP), and quality evaluation standards for stem cells after three-dimensional culture amplification.

To achieve automated 3D stem cell culture,

Huawei BiologicalSchematic diagram of “3D fully automated stem cell amplification process” (Source: official website)

In the progress of 3D stem cell micro-tissue therapy, Huajing Bio has completed diabetic foot lower limb ischemia, bone and cartilage defects, intervertebral disc degeneration, liver fibrosis and skin damage Preclinical efficacy and safety verification of disease models. Currently, downstream stem cell companies and clinical partners are being sought to jointly promote the validation of clinical trials.

3D cell high-throughput drug screening products, 3D micro-array array developed by Huasheng Bio-3D PlaTrixTM cell culture plate can simultaneously screen 384 conditions, and the cycle takes only 7 days. The traditional mouse reagent model takes five to six months from the time of inoculation, tumor formation, and reagent testing.

It is reported that Huasheng Biological has reached cooperation with many universities such as Peking University and Zhejiang University, as well as the stem cell research institutes such as Beijing Stem Cell Bank. At the same time, Liu Wei revealed that the construction of the GMP plant is about to be completed. It is expected that Huasheng Bio will be able to produce the first batch of products by the end of this year, and submit the relevant qualification declaration of technical products.

Team, Huawei BiologicalThe core members are all composed of Tsinghua alumni, and more than 60% of the members are postgraduate. The chief scientist Du Yanan is a tenured professor of Tsinghua University Medical School, a recipient of the National Youth Science Foundation’s Outstanding Youth Fund, and a Yangtze River young scholar; co-founder &CEO Liu Wei, The main inventor of the company’s stem cell industrial production solution technology, published 20 internationally renowned journal articles, applied for and authorized more than 20 patents; co-founder< Span>&CTO鄢晓君,Singapore, Ph.D., Tsinghua University School of Medicine,Just as a teacher Professor Du Yanan.

For investment logic, Guokejia and its managing partner Chen Hongwu said: “In recent years, stem cell therapy has shown great potential in areas such as anti-aging and immunotherapy. The relevant regulations issued by the FDA and NMPA will be clearly Stem cells are regulated and approved as biological ‘drugs’, regulatory regulations are becoming more mature, and the prospects for stem cell therapy are becoming broader. Huaying Bio’s 3D micro-tissue engineering technology can provide a personalized culture and amplification pathway for different stem cell production. It greatly improves the efficiency and quality of stem cell expansion. We invest in Huaying Biological, on the one hand, it recognizes the concept and technical products of Huasheng Biological, on the other hand, Huaying Biological has a great passion and confidence in industrialization. Excellent team.”